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SummaryObjectiveTo evaluate the rates of reliable diagnosis of cirrhosis by two
usual blood tests. Methods Reliable diagnosis was mainly evaluated by comparing
rates of positive (PPV) and negative (NPV) predictive values with FibroTest and
FibroMeters, as either standard test or specifically designed for cirrhosis, in 1056
patients with chronic hepatitis C. Results Using the diagnostic limits provided by
fibrosis stage scales, the PPV for cirrhosis was: standard FibroMeters: 68.5% versus
FibroTest: 37.1%. Using 95% PPV, the cirrhosis detection rate was: specific
FibroMeter: 26.1% versus FibroTest: 2.0% (P< 10−3). The cirrhosis detection rate
increased from 26 to 65% by performing liver biopsy in 8% of patients with
indeterminate results on specific FibroMeter between 95% NPV and PPV. On the
other hand, specific FibroMeter provided three intervals of 95% reliable diagnosis
with no biopsy: less than or equal to 95% NPV: no cirrhosis (threshold: diagnosis);
significant fibrosis; and greater than or equal to 95% PPV: cirrhosis. Conclusion The
detection rate and PPV for cirrhosis using fibrosis scales were fair for standard
FibroMeter and poor for FibroTest. Around one-fourth of cases of cirrhosis are
detected by the 95% PPV of specific FibroMeter, and around two-thirds by
performing an additional liver biopsy in only 8% of patients. Finally, specific
FibroMeter can avoid liver biopsy by classifying patients into three categories: no
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